MCC Offers In-Depth Study of Risk-Based Monitoring Practices Currently Utilized in the Industry - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
MCC Offers In-Depth Study of Risk-Based Monitoring Practices Currently Utilized in the Industry

Source: Applied Clinical Trials

MCC released an in-depth report on risk-based monitoring practices, “Taking the Risk-Based Monitoring Plunge: Who’s doing it, how they’re approaching it, and the metrics they’re using to manage it.” The new RBM Report provides current RBM users the ability to compare the RBM methods they currently employ to those utilized by a large sample of biopharmaceutical, CRO and academic research organizations. The report includes over 40 figures, tables and graphs covering a wide range of topics and is available for purchase through MCC.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here